Based on the Moderna Inc stock forecast from 16 analysts, the average analyst target price for Moderna Inc is USD 64.74 over the next 12 months. Moderna Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Moderna Inc is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Moderna Inc’s stock price was USD 35.21. Moderna Inc’s stock price has changed by +4.85% over the past week, +0.66% over the past month and -63.15% over the last year.
No recent analyst target price found for Moderna Inc
No recent average analyst rating found for Moderna Inc
Company Overview Moderna Inc
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Read Less
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationa...Read More
Frequently Asked Questions About Moderna Inc (MRNA) Stock
Based on ratings from 16 analysts Moderna Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, 9 sell and 15 hold ratings.
Unfortunately we do not have enough data on MRNA's stock to indicate if its a good dividend stock.
Based on targets from 16 analysts, the average taret price for MRNA is USD 64.74 over the next 12 months. The maximum analyst target price is USD 139 while the minimum anlayst target price is USD 27.
MRNA stock's Price/Earning ratio is 25.72.
Our analysis grades MRNA stock's Price / Earning ratio at F. This means that MRNA stock's Price/Earning ratio is above 75% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this MRNA may be a overvalued for its sector.
The last closing price of MRNA's stock was USD 35.21.
The most recent market capitalization for MRNA is USD 12.93B.
Based on targets from 16 analysts, the average taret price for MRNA is projected at USD 64.74 over the next 12 months.
This means that MRNA's stock price may go up by +83.86% over the next 12 months.
We can't find any ETFs which contains Moderna Inc's stock.
As per our most recent records Moderna Inc has 5,600 Employees.
Moderna Inc's registered address is 200 Technology Square, Cambridge, MA, United States, 02139.
You can get more information about it from Moderna Inc's website at https://www.modernatx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Moderna Inc (MRNA) Stock
Based on ratings from 16 analysts Moderna Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, 9 sell and 15 hold ratings.
Unfortunately we do not have enough data on MRNA's stock to indicate if its a good dividend stock.
Based on targets from 16 analysts, the average taret price for MRNA is USD 64.74 over the next 12 months. The maximum analyst target price is USD 139 while the minimum anlayst target price is USD 27.
MRNA stock's Price/Earning ratio is 25.72.
Our analysis grades MRNA stock's Price / Earning ratio at F. This means that MRNA stock's Price/Earning ratio is above 75% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this MRNA may be a overvalued for its sector.
The last closing price of MRNA's stock was USD 35.21.
The most recent market capitalization for MRNA is USD 12.93B.
Based on targets from 16 analysts, the average taret price for MRNA is projected at USD 64.74 over the next 12 months.
This means that MRNA's stock price may go up by +83.86% over the next 12 months.
We can't find any ETFs which contains Moderna Inc's stock.
As per our most recent records Moderna Inc has 5,600 Employees.
Moderna Inc's registered address is 200 Technology Square, Cambridge, MA, United States, 02139.
You can get more information about it from Moderna Inc's website at https://www.modernatx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MRNA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
